{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:03:33Z","timestamp":1784783013585,"version":"3.55.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Malignant melanoma of the female genital tract is rare but highly aggressive. Vulvar malignant melanomas and vaginal malignant melanomas are commonly grouped as vulvovaginal malignant melanoma because of their anatomical proximity, low incidence, and limited disease-specific evidence. However, accumulating clinical, pathological, and biological observations suggest that this conventional grouping may mask important site-related heterogeneity. Vulvar malignant melanoma arises within a complex mucocutaneous transition zone and may partially overlap biologically with cutaneous melanoma, whereas vaginal malignant melanoma more consistently demonstrates features of mucosal melanoma. These distinctions influence patterns of presentation, local extension, lymphatic dissemination, therapeutic feasibility, recurrence behavior, and survival outcomes. Vaginal malignant melanoma is frequently diagnosed at a more advanced stage because of occult symptoms and challenging local control, contributing to its particularly poor prognosis. In contrast, vulvar malignant melanoma encompasses a broader biological spectrum that may require subsite-specific interpretation. Although both entities belong to the spectrum of lower female genital tract melanoma, emerging evidence indicates that they should not be treated as interchangeable diseases in either research design or clinical management. This review synthesizes current evidence regarding the overlap and divergence between vulvar and vaginal malignant melanoma and advocates for a site-a\n                    <jats:sup>1<\/jats:sup>\n                    ware framework to guide future translational research, surgical decision-making, and systemic treatment strategies.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1907495","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:30:01Z","timestamp":1784781001000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Vulvar malignant melanoma versus vaginal malignant melanoma: distinct biology, distinct clinical behavior, and distinct management?"],"prefix":"10.3389","volume":"16","author":[{"given":"Fangyu","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Gynecology, Gynecology Department, Hubei Provincial Hospital of Integrated Chinese and Western Medicine","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2022.11.002","article-title":"Different clinico-pathological and prognostic features of vulvar, vaginal, and cervical melanomas","volume":"131","author":"Wu","year":"2023","journal-title":"Hum Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000198","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for vulvovaginal melanomas","volume":"24","author":"Leitao","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e257081","DOI":"10.6004\/jnccn.2025.7081","article-title":"Modern management of newly diagnosed vulvovaginal melanoma","volume":"24","author":"Leitao","year":"2026","journal-title":"J Natl Compr Cancer Netw"},{"key":"B4","doi-asserted-by":"publisher","first-page":"111368","DOI":"10.1016\/j.ejso.2025.111368","article-title":"Surgical treatment of vaginal and vulvar melanoma: a 18-year retrospective study","volume":"52","author":"Dabreteau","year":"2026","journal-title":"EJSO"},{"key":"B5","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3390\/jpm15110551","article-title":"Comparative insights into cutaneous, mucosal, and vulvovaginal melanomas: Biology, targeted therapies, and survival with a focus on immune checkpoint inhibitors","volume":"15","author":"Christmas","year":"2025","journal-title":"J Personal Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"104435","DOI":"10.1016\/j.critrevonc.2024.104435","article-title":"Heterogeneous pathogenesis of melanoma: BRAF mutations and beyond","volume":"201","author":"Colombino","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1056\/NEJMicm2509511","article-title":"Vulvar melanoma with vaginal extension","volume":"394","author":"Castro-Apodaca","year":"2026","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e17656","DOI":"10.1200\/JCO.2025.43.16_suppl.e17656","article-title":"Survival outcomes in gynecologic melanomas: A population-based analysis","volume":"43","author":"Akerele","year":"2025","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-005359","article-title":"The prognostic value of tumor-infiltrating lymphocytes in vulvovaginal melanoma","volume":"34","author":"Vanbockstael","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"104469","DOI":"10.1016\/j.esmoop.2025.104469","article-title":"155P Advancing prognostic models for vaginal and vulvar melanomas: Machine learning insights and treatment implications","volume":"10","author":"Alshwayyat","year":"2025","journal-title":"ESMO Open"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0036","article-title":"NCCN guidelines\u00ae Insights: melanoma: cutaneous, version 2","volume":"22","author":"Swetter","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"102542","DOI":"10.1016\/j.ijgc.2025.102542","article-title":"Surviving vulvar melanoma: a glimpse of light in the darkness","volume":"35","author":"Parroco","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"114303","DOI":"10.1016\/j.ejca.2024.114303","article-title":"Value of surgical lymph node assessment for patients with vulvar melanoma","volume":"210","author":"Giannopoulos","year":"2024","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036128","article-title":"Treatment of primary vaginal Malignant melanoma and review of previous literature: A case report","volume":"102","author":"Bai","year":"2023","journal-title":"Med (Baltimore)"},{"key":"B16","article-title":"NCCN guidelines version 3.2024 vulvar cancer","year":"2023"},{"key":"B17","doi-asserted-by":"publisher","first-page":"155404","DOI":"10.1016\/j.prp.2024.155404","article-title":"PRAME expression in genital melanocytic lesions - Potential diagnostic pitfall of intermediate expression in atypical genital nevi","author":"Ng","year":"2024","journal-title":"Pathol Res Pract"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.3390\/cancers15164026","article-title":"BRAF mutations in melanoma: Biological aspects, therapeutic implications, and circulating biomarkers","volume":"15","author":"Castellani","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.3390\/cancers14205123","article-title":"Cutaneous melanoma versus vulvovaginal melanoma-risk factors, pathogenesis and comparison of immunotherapy efficacy","volume":"14","author":"Lorenz","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00614-7","article-title":"Vulvar melanoma: Molecular characteristics, diagnosis, surgical management, and medical treatment","volume":"22","author":"Wohlmuth","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/1541-7786.MCR-20-0839","article-title":"Meta-analysis and systematic review of the genomics of mucosal melanoma","volume":"19","author":"Broit","year":"2021","journal-title":"Mol Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.3390\/cells10092216","article-title":"Prognostic roles of BRAF, KIT, NRAS, IGF2R and SF3B1 mutations in mucosal melanomas","volume":"10","author":"Wr\u00f3blewska","year":"2021","journal-title":"Cells"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.702287","article-title":"Mucosal melanoma: Pathological evolution, pathway dependency and targeted therapy","volume":"11","author":"Ma","year":"2021","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2022.01.003","article-title":"Genitourinary melanoma: An overview for the clinician","volume":"9","author":"DePalo","year":"2022","journal-title":"Asian J Urol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1186\/s12885-021-08427-x","article-title":"Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract","volume":"21","author":"Cai","year":"2021","journal-title":"BMC Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0013","article-title":"Vulvar cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Abu-Rustum","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B27","year":"2025"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.70390","article-title":"Cancer of the vulva: 2025 update: FIGO Cancer Report 2025","volume":"171","author":"Olawaiye","year":"2025","journal-title":"Int J Gynecol Obstetr"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1615749","article-title":"Diagnosis and treatment of 33 patients with primary melanoma of the female reproductive system","volume":"15","author":"Gao","year":"2025","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70014","article-title":"Comprehensive management of vulvovaginal cancers","volume":"75","author":"Nogueira-Rodrigues","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B31","doi-asserted-by":"publisher","first-page":"101268","DOI":"10.1016\/j.gore.2023.101268","article-title":"Margin status in vulvovaginal melanoma: Management and oncologic outcomes of 50 cases","volume":"49","author":"Straubhar","year":"2023","journal-title":"Gynecol Oncol Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2024.101483","article-title":"Treatment outcomes of vulvar and vaginal melanoma at an NCCN institution between 1993 and 2021","volume":"55","author":"Ostby","year":"2024","journal-title":"Gynecol Oncol Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ygyno.2021.01.018","article-title":"Evaluation of treatment, prognostic factors, and survival in 198 vulvar melanoma patients: implications for clinical practice","volume":"161","author":"Boer","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/jpm16020070","article-title":"Primary clitoral melanoma: Personalized therapeutic strategies informed by clinical evidence and systematic review","volume":"16","author":"Pitsillidi","year":"2026","journal-title":"J Personal Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.09.026","article-title":"Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression","volume":"167","author":"Mitra","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.01.011","article-title":"Lymphatic mapping and sentinel node biopsy in vulvar melanoma: the first multicenter study and systematic review","volume":"170","author":"Collarino","year":"2023","journal-title":"Gynecol Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2020.04.030","article-title":"Ano-uro-genital mucosal melanoma UK national guidelines","volume":"135","author":"Smith","year":"2020","journal-title":"Eur J Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ijgo.70325","article-title":"Cancer of the vagina: 2025 update","author":"Adams","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e01222","DOI":"10.1136\/jitc-2025-012225","article-title":"International real-world study of combination immunotherapy sequences in metastatic melanoma","volume":"13","author":"Guardamagna","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3390\/cancers16101794","article-title":"Angiogenesis still plays a crucial role in human melanoma progression","volume":"16","author":"Cazzato","year":"2024","journal-title":"Cancers"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.3390\/ijms26083828","article-title":"Current treatment paradigms for advanced melanoma with brain metastases","volume":"26","author":"Bonzano","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1322515","DOI":"10.3389\/fonc.2024.1322515","article-title":"Stereotactic body radiotherapy as a viable treatment on extracranial oligometastases in melanoma patients: a retrospective multicentric study","volume":"14","author":"Trentesaux","year":"2024","journal-title":"Front Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.15155","article-title":"Long-term quality of life, vulvar symptoms, and sexual functioning: A cross-sectional study of Norwegian vulvar cancer survivors","volume":"104","author":"Meltzer-Gunnes","year":"2025","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.3390\/jcm13133771","article-title":"Survival and treatment modalities in primary vaginal melanoma-case report and a narrative review","volume":"13","author":"Guzik","year":"2024","journal-title":"J Clin Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/sexmed\/qfaf0066","article-title":"Clinical practice guidelines: sexual dysfunction in gynecological cancer patients","volume":"13","author":"Peleg Nesher","year":"2025","journal-title":"Sex Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.14710","article-title":"Anxiety and depression among women with newly diagnosed vulvar cancer - A nationwide longitudinal study","volume":"103","author":"Zach","year":"2024","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000001012","article-title":"Clinical features of vulvar and vaginal Malignant melanomas and the effects of immune checkpoint inhibitors in Japanese patients: a single-center, retrospective cohort study","volume":"35","author":"Horisaki","year":"2025","journal-title":"Melanoma Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00487-x","article-title":"Malignant melanoma of the vulva and vagina: A US population-based study of 1863 patients","volume":"21","author":"Wohlmuth","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30473","article-title":"Vulvar and vaginal melanoma: a unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma","volume":"123","author":"Hou","year":"2017","journal-title":"Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181fb8045","article-title":"Primary Malignant melanoma of the vagina","volume":"116","author":"Frumovitz","year":"2010","journal-title":"Obstet Gynecol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000768","article-title":"Prognostic factors of recurrence and survival in vulvar melanoma: subgroup analysis of the VULvar CANcer study","volume":"26","author":"Iacoponi","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115152","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 1: diagnostics - update 2024","volume":"215","author":"Garbe","year":"2025","journal-title":"Eur J Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115153","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - update 2024","volume":"215","author":"Garbe","year":"2025","journal-title":"Eur J Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03497-2","article-title":"SEOM-GEM clinical guidelines for cutaneous melanoma (2023)","volume":"26","author":"M\u00e1rquez-Rodas","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.211","article-title":"Comparison of molecular abnormalities in vulvar and vaginal melanomas","volume":"27","author":"Aulmann","year":"2014","journal-title":"Mod Pathol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1907495\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:30:02Z","timestamp":1784781002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1907495\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":57,"alternative-id":["10.3389\/fonc.2026.1907495"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1907495","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"1907495"}}